Phase 3 Readout
MLTX: Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
September 28, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 28, 2026
- Company
- MoonLake Immunotherapeutics (MLTX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
- Indication
- Hidradenitis Suppurativa